Sweet syndrome in patients with and without malignancy: a retrospective study of 66 cases from a tertiary care centre (notice n° 604912)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 02156cam a2200217 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250121155505.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Titou, Hicham |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | Sweet syndrome in patients with and without malignancy: a retrospective study of 66 cases from a tertiary care centre |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2024.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 87 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | BackgroundSweet syndrome is a neutrophilic dermatosis that may be associated with malignancy, particularly haematological malignancy. Considering its rarity, the clinical characteristics of Sweet syndrome are still unclear.ObjectivesWe aimed to analyse clinicopathological characteristics, treatment, and outcomes of patients with Sweet syndrome according to concurrent malignancy.Materials & MethodsWe retrospectively reviewed patients with Sweet syndrome at the Department of Dermatology from January 2001 to August 2021.ResultsWe identified 66 patients (median age: 58 years old; 57.6% male) with Sweet syndrome: 24.2% with the classic form, 36.3% with the malignancy-associated form, and 15.1% with the drug-induced form. Idiopathic Sweet syndrome was most common in the non-malignancy group (18.1%). Leukopenia (p = 0.008), anaemia (p = 0.004), and thrombocytopenia (p = 0.013) were significantly associated with malignancy. No significant difference in histopathology was identified between patients with and without haematological malignancy. Systemic corticosteroids were the most commonly used therapy (n=44, 66.6%). Relapse of Sweet syndrome was more prevalent in the malignancy group.ConclusionPatients with Sweet syndrome who have laboratory evidence of leukopenia, anaemia and thrombocytopenia should be investigated for malignancy. Sweet syndrome often occurs as a paraneoplastic feature. |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | treatment relapse |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | Sweet syndrome |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | malignancy |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | neutrophilic dermatosis |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Bouhamidi, Ahmed |
| Relator term | author |
| 786 0# - DATA SOURCE ENTRY | |
| Note | European Journal of Dermatology | 34 | 5 | 2024-11-09 | p. 517-524 | 1167-1122 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://shs.cairn.info/revue-european-journal-of-dermatology-2024-5-page-517?lang=en&redirect-ssocas=7080">https://shs.cairn.info/revue-european-journal-of-dermatology-2024-5-page-517?lang=en&redirect-ssocas=7080</a> |
Pas d'exemplaire disponible.
Réseaux sociaux